Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v15-FR Version v10-EN
Language French English
Date Updated 2017-05-15 2017-05-05
Drug Identification Number 00466085 00466085
Brand name M-M-R II M-M-R II
Common or Proper name (measles, mumps and rubella virus vaccine, live, attenuated) Lyophilized powder for injection (measles, mumps and rubella virus vaccine, live, attenuated) Lyophilized powder for injection
Company Name MERCK CANADA INC MERCK CANADA INC
Ingredients MEASLES VIRUS VACCINE LIVE ATTENUATED; MUMPS VIRUS VACCINE LIVE ATTENUATED (JERYL LYNN STRAIN); RUBELLA VIRUS VACCINE LIVE ATTENUATED (WISTAR RA27/3 STRAIN) MEASLES VIRUS VACCINE LIVE ATTENUATED; MUMPS VIRUS VACCINE LIVE ATTENUATED (JERYL LYNN STRAIN); RUBELLA VIRUS VACCINE LIVE ATTENUATED (WISTAR RA27/3 STRAIN)
Strength(s) 0.5 mL dose after reconstitution Measles: ≥1000 CCID50 Mumps: ≥5000 CCID50 Rubella: ≥1000 CCID50 0.5 mL dose after reconstitution Measles: ≥1000 CCID50 Mumps: ≥5000 CCID50 Rubella: ≥1000 CCID50
Dosage form(s) Powder For Solution Powder For Solution
Route of administration Subcutaneous Subcutaneous
Packaging size 10x1dose 10x1dose
ATC code J07BD J07BD
ATC description VIRAL VACCINES VIRAL VACCINES
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date 2017-05-10 2017-05-10
Actual start date 2017-05-11
Estimated end date 2017-05-20 2017-05-20
Actual end date 2017-05-12
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments